Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
RESEARCH TOOLSreports
Holding ARVN?
Track your performance easily
ARVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$17.37 - $53.08
Previous Close$18.48
Volume1.76M
Average Volume (3M)719.11K
Market Cap
$1.27B
Enterprise Value$149.72M
Total Cash (Recent Filing)$1.12B
Total Debt (Recent Filing)$1.50M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Mar 03, 2025EPS Estimate
-$0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.67
Shares Outstanding68,713,098
10 Day Avg. Volume1,222,308
30 Day Avg. Volume719,111
Standard Deviation0.38
R-Squared0.06
Alpha0.00815
Financial Highlights & Ratios
Price to Book (P/B)2.17
Price to Sales (P/S)7.88
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.93
Enterprise Value/Gross Profit1.91
Enterprise Value/Ebitda-0.47
Forecast
1Y Price Target
$65.64Price Target Upside255.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Arvinas Holding Company News
PremiumCompany Announcements
Arvinas and Pfizer Report Promising Cancer Study Results
Bulls Say, Bears Say
Bulls Say
Competitive PositioningARVN emerged from the conference with confidence in their competitive profile in mBC and plans to provide several program updates.
Market DifferentiationMarket differentiation from SERDS is seen as a key driver for stock upside and increased investor appreciation.
Program DevelopmentManagement expresses high excitement for their LRRK2 (neuro) and BCL6 (lymphoma) degrader programs, indicating the story is not just focused on mBC.
Bears Say
Adverse EventsThe rate of discontinuations and gastrointestinal side effects in EMBER-3 are considered problematic for patients.
Clinical Trial ResultsThe EMBER-3 combo data is underwhelming and not significantly superior to existing studies.
Study Design ConcernsThe VERITAC-2 study is not powered to detect statistical significance in the ESR1-wild-type population.
---
Ownership Overview
2.66% Insiders
25.24% Mutual Funds
47.88% Other Institutional Investors
8.62% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $17.37 and its highest was $53.08 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Currently, no data Available
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Mar 03, 2025 which is in 71 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on Oct 30, 2024. The company reported -$0.68 earnings per share for the quarter, beating the consensus estimate of -$0.843 by $0.163.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -$0.96.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 68,713,100 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of -$0.68 in its last earnings report, beating expectations of -$0.843. Following the earnings report the stock price went up 0.582%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Among the largest hedge funds holding Arvinas Holding Company’s share is New Leaf Venture Partners, L.L.C.. It holds Arvinas Holding Company’s shares valued at 35M.
---
Arvinas Holding Company Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.64 (255.19% Upside)
$65.64 (255.19% Upside)
Hedge Fund Trend
Increased
By 551.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.30%
12-Months-Change
Fundamentals
Return on Equity
-59.16%
Trailing 12-Months
Asset Growth
10.28%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
---
ARVN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, highlighting significant revenue growth, a strong financial position, and promising advancements in their pipeline, particularly the vepdegestrant program. However, there are concerns about increased expenses and dependency on future clinical trial data.Read More>---
ARVN Stock 12 Month Forecast
Average Price Target
$65.64
▲(255.19% Upside)
Technical Analysis
Blueprint Medicines
―
Rocket Pharmaceuticals
―
Fate Therapeutics
―
Heron Therapeutics
―
Best Analysts Covering ARVN
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+14.28%
reiterated a buy rating 7 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +14.28% per trade.
---